Literature DB >> 23267944

[A case of pancreaticoduodenectomy for duodenal carcinoma with a replaced common hepatic artery running through the pancreatic parenchyma].

Isamu Hosokawa1, Hiroaki Shimizu, Masayuki Nakajima, Hiroyuki Yoshidome, Masayuki Ohtsuka, Atsushi Kato, Hideyuki Yoshitomi, Katsunori Furukawa, Dan Takeuchi, Tsukasa Takayashiki, Satoshi Kuboki, Daisuke Suzuki, Masaru Miyazaki.   

Abstract

To perform safe and radical pancreaticoduodenectomy, adequate knowledge of the branching and running course of the common hepatic artery is necessary. Formation of a common trunk by the common hepatic artery and superior mesenteric artery, called the hepatomesenteric trunk, is very rare. When it occurs, the common hepatic artery arising from the hepatomesenteric trunk usually runs behind the pancreas head. In the present case, however, it ran through the pancreatic parenchyma. Therefore, pancreaticoduodenectomy for duodenal carcinoma was performed with preservation of the intrapancreatic common hepatic artery. When pancreaticoduodenectomy is performed in patients with a replaced common hepatic artery running through the pancreatic parenchyma, it is necessary to preoperatively determine whether to preserve or resect the common hepatic artery in the pancreas with consideration of the curability. If resected, whether to reconstruct it must also be determined. If reconstructed, the reconstruction method must be determined, and if not, it is important to perform preoperative coiling of the common hepatic artery and intraoperative measurement of the hepatic blood flow with a Doppler flow meter.

Entities:  

Mesh:

Year:  2012        PMID: 23267944

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  1 in total

1.  Awareness of hepatic arterial variants is required in surgical oncology decision making strategy: Case report and review of literature.

Authors:  Robert Sitarz; Monika Berbecka; Jerzy Mielko; Karol Rawicz-Pruszyński; Grzegorz Staśkiewicz; Ryszard Maciejewski; Wojciech Polkowski
Journal:  Oncol Lett       Date:  2018-02-22       Impact factor: 2.967

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.